Q-Sub Guidance Needs Clarity On Informal Meetings And Timelines, Say Commenters

Stakeholders say the US FDA’s Q-sub guidance could use some tweaking, especially for identifying when informal meetings with the agency are more appropriate than formal ones and creating less burdensome timelines.